Exact Sciences (NASDAQ: EXAS) reported Q2 EPS of ($0.30), $0.03 better than the analyst estimate of ($0.33). Revenue for the quarter came in at $102.9 million versus the consensus estimate of $104.66 million.

GUIDANCE:

Exact Sciences sees FY2018 revenue of $420-430 million, versus the consensus of $435.8 million.

For earnings history and earnings-related data on Exact Sciences (EXAS) click here.